Q2 2025 Exagen Inc Earnings Call Transcript
Key Points
- Exagen Inc (XGN) reported record revenue of $17.2 million for Q2 2025, marking a 14% year-over-year growth.
- The AVISE CTD test volume saw substantial growth, driven organically by the existing commercial team and increased clinical recognition.
- Revenue per territory increased significantly, showcasing strong commercial leverage and execution.
- The company successfully launched new biomarkers, which have been well-received by clinicians and are driving clinical conversations.
- Exagen Inc (XGN) ended the quarter with over $30 million in cash and equivalents, providing financial flexibility for future growth investments.
- Operating expenses increased to $13 million, up from $11.6 million in the same quarter last year, due to one-time expenses and continued R&D investments.
- The net loss for the quarter was $4.4 million, compared to $3 million in the same period last year, impacted by new debt facility costs.
- The company faces challenges in achieving immediate profitability, with a focus on long-term growth and investment.
- There is a potential headwind from traditional seasonality in the back half of the year, which could impact sales volume.
- The ASP (Average Selling Price) increase is progressing slower than anticipated, with adjustments made to align with actual cash collections.
Greetings and welcome to the Exagen Inc Q2 2025 earnings call.
(Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ryan Douglas, Investor Relations.
Thank you. You may begin.
Good morning and thank you for joining us.
Earlier this morning, Exagen Inc released financial results for the quarter ended June 30, 2025. John Aballi, our President and Chief Executive Officer; and Jeff Black, our Chief Financial Officer, will host this morning's call. The recording of today's call and the press release announcing the quarterly results can be found on the company's website at www.exagen.com.
As today's call includes forward-looking statements, we encourage you to review the statements contained in today's press release, and the risk and uncertainties described in our SEC filings, which identify certain factors that may cause the company's actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
